RT Journal Article
T1 Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
A1 Sarink, Danja
A1 Schock, Helena
A1 Johnson, Theron
A1 Overvad, Kim
A1 Holm, Marianne
A1 Tjønneland, Anne
A1 Boutron-Ruault, Marie-Christine
A1 His, Mathilde
A1 Kvaskoff, Marina
A1 Boeing, Heiner
A1 Lagiou, Pagona
A1 Papatesta, Eleni-Maria
A1 Trichopoulou, Antonia
A1 Palli, Domenico
A1 Pala, Valeria
A1 Mattiello, Amalia
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Bueno-de-Mesquita, H B As
A1 van Gils, Carla H
A1 Peeters, Petra H
A1 Weiderpass, Elisabete
A1 Agudo, Antonio
A1 Sanchez-Perez, Maria-Jose
A1 Chirlaque, Maria-Dolores
A1 Ardanaz, Eva
A1 Amiano, Pilar
A1 Khaw, Kay Tee
A1 Travis, Ruth
A1 Dossus, Laure
A1 Gunter, Mark
A1 Rinaldi, Sabina
A1 Merritt, Melissa
A1 Riboli, Elio
A1 Kaaks, Rudolf
A1 Fortner, Renée T
AB Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1,976 incident invasive breast cancer cases [estrogen receptor positive (ER+), n = 1,598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet = 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63); Ptrend = 0.20], but not ER- disease. For both ER+ and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR- disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14); Ptrend = 0.03]. This study provides the first large-scale prospective data on circulating sRANKL and breast cancer. We observed limited evidence for an association between sRANKL and breast cancer risk. Cancer Prev Res; 10(9); 525-34. ©2017 AACR.
YR 2017
FD 2017-07-12
LK http://hdl.handle.net/10668/11398
UL http://hdl.handle.net/10668/11398
LA en
DS RISalud
RD Apr 8, 2025